Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2018 | CheckMate 032: nivolumab/ipilimumab for urothelial carcinoma

Jonathan Rosenberg • 18 Jan 2019
ESMO 2018
Bladder Cancer Genitourinary Cancer Checkpoint Inhibitors Ipilimumab Nivolumab
CheckMate 032

Jonathan Rosenberg, MD, of Memorial Sloan Kettering Cancer Center, New York City, NY, discusses results from the Phase I/II CheckMate 032 trial (NCT01928394), where the nivolumab/ipilimumab combination was compared with nivolumab monotherapy in urothelial carcinoma. A higher dose of ipilimumab in the combination therapy seemed to result in improved anti-cancer activity compared to nivolumab alone; however, Dr Rosenberg advises caution as the data is immature. This video was recorded at the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany.

More from Jonathan Rosenberg

The future of antibody-drug conjugates in urothelial carcinoma
1:39
The future of antibody-drug conjugates in urothelial carcinoma
Jonathan Rosenberg • 16 Sep 2024
What is the optimal duration of treatment of enfortumab vedotin in urothelial carcinoma?
1:35
What is the optimal duration of treatment of enfortumab vedotin in urothelial carcinoma?
Jonathan Rosenberg • 16 Sep 2024
NKT2152, an oral HIF-2α inhibitor, in pre-treated advanced clear cell renal carcinoma
1:31
NKT2152, an oral HIF-2α inhibitor, in pre-treated advanced clear cell renal carcinoma
Jonathan Rosenberg • 16 Sep 2024
5-year follow-up of EV and pembrolizumab for la/mUC in the EV-103 trial
1:30
5-year follow-up of EV and pembrolizumab for la/mUC in the EV-103 trial
Jonathan Rosenberg • 16 Sep 2024

Related Videos

Current and emerging systemic strategies in biochemically relapsed prostate cancer
2:45
Current and emerging systemic strategies in biochemically relapsed prostate cancer
Ashwin Sachdeva • 16 May 2026
How has SABR improved radiotherapy practice in kidney cancer?
1:06
How has SABR improved radiotherapy practice in kidney cancer?
Shankar Siva • 16 May 2026
Which patients with kidney cancer may benefit from SABR treatment?
1:58
Which patients with kidney cancer may benefit from SABR treatment?
Shankar Siva • 16 May 2026
Management of brain metastasis in patients with poor-risk testicular cancer
1:03
Management of brain metastasis in patients with poor-risk testicular cancer
Darren Feldman • 30 May 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals